South Florida Research Solutions LLC

1. Novartis Pharmaceuticals Corporation $182,273 10 payments
2. AbbVie, Inc. $113,954 33 payments
3. Boehringer Ingelheim Pharmaceuticals, Inc. $16,977 3 payments
4. Organon LLC $2,471 3 payments
5. Amgen Inc. $2,250 1 payment
6. Eisai Inc. $1,200 1 payment

1. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $148,028 4 payments
2. M16-100 $90,214 22 payments
3. An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $34,245 6 payments
4. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $23,740 11 payments
5. GLORIA AF Registry Phase II III Core $16,977 3 payments
6. 1242-035 $2,471 3 payments
7. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction $2,250 1 payment
8. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors $1,200 1 payment

1. Patient care $2,471 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.